A Case of Etanercept Treatment in a Patient with Ankylosing Spondylitis on Peritoneal Dialysis
Journal of Rheumatic Diseases
; : 361-363, 2013.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-173304
Responsible library:
WPRO
ABSTRACT
Treatments for patient with ankylosing spondylitis (AS) include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) and anti-tumor necrosis factor-alpha (TNFalpha) agents. However, owing to the well-known nephrotoxicity of NSAIDs and some DMARDs, the use of these drugs is limited in AS patients with renal insufficiency. As the pharmacokinetics and metabolism of anti-TNFalpha agents in patients of end stage renal disease, especially those receiving peritoneal dialysis (PD), have not been investigated well, little is known about treating them with anti-TNFalpha agents. We described the safety and efficacy of etanercept, a soluble fusion protein comprising the TNF receptor 2 in linkage with the Fc portion of immunoglobulin G, in a 40-year-old male AS patient receiving PD.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Spondylitis, Ankylosing
/
Immunoglobulin G
/
Pharmacokinetics
/
Anti-Inflammatory Agents, Non-Steroidal
/
Peritoneal Dialysis
/
Tumor Necrosis Factor-alpha
/
Receptors, Tumor Necrosis Factor
/
Antirheumatic Agents
/
Renal Insufficiency
/
Etanercept
Limits:
Adult
/
Humans
/
Male
Language:
English
Journal:
Journal of Rheumatic Diseases
Year:
2013
Document type:
Article